Antibiotics inhibit tumor and disease activity in cutaneous T cell lymphoma

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Antibiotics inhibit tumor and disease activity in cutaneous T cell lymphoma. / Lindahl, Lise M; Willerslev-Olsen, Andreas; Gjerdrum, Lise M R; Nielsen, Pia R; Blümel, Edda; Rittig, Anne H; Celis, Pamela; Herpers, Bjorn; Becker, Jürgen C; Stausbøl-Grøn, Birgitte; Wasik, Mariusz A; Gluud, Maria; Fredholm, Simon; Buus, Terkild B; Johansen, Claus; Nastasi, Claudia; Peiffer, Lukas; Kubat, Linda; Bzorek, Michael; Eriksen, Jens O; Krejsgaard, Thorbjørn; Bonefeld, Charlotte M; Geisler, Carsten; Mustelin, Tomas; Langhoff, Erik; Givskov, Michael; Woetmann, Anders; Kilian, Mogens; Litman, Thomas; Iversen, Lars; Odum, Niels.

In: Blood, Vol. 134, No. 13, 26.09.2019, p. 1072-1083.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Lindahl, LM, Willerslev-Olsen, A, Gjerdrum, LMR, Nielsen, PR, Blümel, E, Rittig, AH, Celis, P, Herpers, B, Becker, JC, Stausbøl-Grøn, B, Wasik, MA, Gluud, M, Fredholm, S, Buus, TB, Johansen, C, Nastasi, C, Peiffer, L, Kubat, L, Bzorek, M, Eriksen, JO, Krejsgaard, T, Bonefeld, CM, Geisler, C, Mustelin, T, Langhoff, E, Givskov, M, Woetmann, A, Kilian, M, Litman, T, Iversen, L & Odum, N 2019, 'Antibiotics inhibit tumor and disease activity in cutaneous T cell lymphoma', Blood, vol. 134, no. 13, pp. 1072-1083. https://doi.org/10.1182/blood.2018888107

APA

Lindahl, L. M., Willerslev-Olsen, A., Gjerdrum, L. M. R., Nielsen, P. R., Blümel, E., Rittig, A. H., Celis, P., Herpers, B., Becker, J. C., Stausbøl-Grøn, B., Wasik, M. A., Gluud, M., Fredholm, S., Buus, T. B., Johansen, C., Nastasi, C., Peiffer, L., Kubat, L., Bzorek, M., ... Odum, N. (2019). Antibiotics inhibit tumor and disease activity in cutaneous T cell lymphoma. Blood, 134(13), 1072-1083. https://doi.org/10.1182/blood.2018888107

Vancouver

Lindahl LM, Willerslev-Olsen A, Gjerdrum LMR, Nielsen PR, Blümel E, Rittig AH et al. Antibiotics inhibit tumor and disease activity in cutaneous T cell lymphoma. Blood. 2019 Sep 26;134(13):1072-1083. https://doi.org/10.1182/blood.2018888107

Author

Lindahl, Lise M ; Willerslev-Olsen, Andreas ; Gjerdrum, Lise M R ; Nielsen, Pia R ; Blümel, Edda ; Rittig, Anne H ; Celis, Pamela ; Herpers, Bjorn ; Becker, Jürgen C ; Stausbøl-Grøn, Birgitte ; Wasik, Mariusz A ; Gluud, Maria ; Fredholm, Simon ; Buus, Terkild B ; Johansen, Claus ; Nastasi, Claudia ; Peiffer, Lukas ; Kubat, Linda ; Bzorek, Michael ; Eriksen, Jens O ; Krejsgaard, Thorbjørn ; Bonefeld, Charlotte M ; Geisler, Carsten ; Mustelin, Tomas ; Langhoff, Erik ; Givskov, Michael ; Woetmann, Anders ; Kilian, Mogens ; Litman, Thomas ; Iversen, Lars ; Odum, Niels. / Antibiotics inhibit tumor and disease activity in cutaneous T cell lymphoma. In: Blood. 2019 ; Vol. 134, No. 13. pp. 1072-1083.

Bibtex

@article{9455f561a7cd459e9cc62cdbbeb9dd7f,
title = "Antibiotics inhibit tumor and disease activity in cutaneous T cell lymphoma",
abstract = "It has been proposed that CD4 T cell responses to Staphylococcus aureus (SA) can inadvertently enhance neoplastic progression in models of skin cancer and cutaneous T cell lymphoma (CTCL). In this prospective study, we explored the effect of transient antibiotic treatment on tumor cells and disease activity in eight patients with advanced stage CTCL. All patients experienced significant decrease in clinical symptoms in response to aggressive, transient antibiotic treatment. In some patients, clinical improvements lasted for more than 8 months. In six out of eight patients, a malignant T cell clone could be identified in lesional skin, and a significant decrease in the fraction of malignant T cells was observed following antibiotics but an otherwise unchanged treatment regimen. Immunohistochemistry, global mRNA expression, and cell-signaling pathway analysis indicated that transient aggressive antibiotic therapy was associated with decreased expression of IL-2 high-affinity receptors (CD25), STAT3 signaling, and cell proliferation in lesional skin. In conclusion, this study provides novel evidence suggesting that aggressive antibiotic treatment inhibits malignant T cells in lesional skin. Thus, we provide a novel rationale for treatment of SA in advanced CTCL.",
author = "Lindahl, {Lise M} and Andreas Willerslev-Olsen and Gjerdrum, {Lise M R} and Nielsen, {Pia R} and Edda Bl{\"u}mel and Rittig, {Anne H} and Pamela Celis and Bjorn Herpers and Becker, {J{\"u}rgen C} and Birgitte Stausb{\o}l-Gr{\o}n and Wasik, {Mariusz A} and Maria Gluud and Simon Fredholm and Buus, {Terkild B} and Claus Johansen and Claudia Nastasi and Lukas Peiffer and Linda Kubat and Michael Bzorek and Eriksen, {Jens O} and Thorbj{\o}rn Krejsgaard and Bonefeld, {Charlotte M} and Carsten Geisler and Tomas Mustelin and Erik Langhoff and Michael Givskov and Anders Woetmann and Mogens Kilian and Thomas Litman and Lars Iversen and Niels Odum",
note = "Copyright {\textcopyright} 2019 American Society of Hematology.",
year = "2019",
month = sep,
day = "26",
doi = "10.1182/blood.2018888107",
language = "English",
volume = "134",
pages = "1072--1083",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "13",

}

RIS

TY - JOUR

T1 - Antibiotics inhibit tumor and disease activity in cutaneous T cell lymphoma

AU - Lindahl, Lise M

AU - Willerslev-Olsen, Andreas

AU - Gjerdrum, Lise M R

AU - Nielsen, Pia R

AU - Blümel, Edda

AU - Rittig, Anne H

AU - Celis, Pamela

AU - Herpers, Bjorn

AU - Becker, Jürgen C

AU - Stausbøl-Grøn, Birgitte

AU - Wasik, Mariusz A

AU - Gluud, Maria

AU - Fredholm, Simon

AU - Buus, Terkild B

AU - Johansen, Claus

AU - Nastasi, Claudia

AU - Peiffer, Lukas

AU - Kubat, Linda

AU - Bzorek, Michael

AU - Eriksen, Jens O

AU - Krejsgaard, Thorbjørn

AU - Bonefeld, Charlotte M

AU - Geisler, Carsten

AU - Mustelin, Tomas

AU - Langhoff, Erik

AU - Givskov, Michael

AU - Woetmann, Anders

AU - Kilian, Mogens

AU - Litman, Thomas

AU - Iversen, Lars

AU - Odum, Niels

N1 - Copyright © 2019 American Society of Hematology.

PY - 2019/9/26

Y1 - 2019/9/26

N2 - It has been proposed that CD4 T cell responses to Staphylococcus aureus (SA) can inadvertently enhance neoplastic progression in models of skin cancer and cutaneous T cell lymphoma (CTCL). In this prospective study, we explored the effect of transient antibiotic treatment on tumor cells and disease activity in eight patients with advanced stage CTCL. All patients experienced significant decrease in clinical symptoms in response to aggressive, transient antibiotic treatment. In some patients, clinical improvements lasted for more than 8 months. In six out of eight patients, a malignant T cell clone could be identified in lesional skin, and a significant decrease in the fraction of malignant T cells was observed following antibiotics but an otherwise unchanged treatment regimen. Immunohistochemistry, global mRNA expression, and cell-signaling pathway analysis indicated that transient aggressive antibiotic therapy was associated with decreased expression of IL-2 high-affinity receptors (CD25), STAT3 signaling, and cell proliferation in lesional skin. In conclusion, this study provides novel evidence suggesting that aggressive antibiotic treatment inhibits malignant T cells in lesional skin. Thus, we provide a novel rationale for treatment of SA in advanced CTCL.

AB - It has been proposed that CD4 T cell responses to Staphylococcus aureus (SA) can inadvertently enhance neoplastic progression in models of skin cancer and cutaneous T cell lymphoma (CTCL). In this prospective study, we explored the effect of transient antibiotic treatment on tumor cells and disease activity in eight patients with advanced stage CTCL. All patients experienced significant decrease in clinical symptoms in response to aggressive, transient antibiotic treatment. In some patients, clinical improvements lasted for more than 8 months. In six out of eight patients, a malignant T cell clone could be identified in lesional skin, and a significant decrease in the fraction of malignant T cells was observed following antibiotics but an otherwise unchanged treatment regimen. Immunohistochemistry, global mRNA expression, and cell-signaling pathway analysis indicated that transient aggressive antibiotic therapy was associated with decreased expression of IL-2 high-affinity receptors (CD25), STAT3 signaling, and cell proliferation in lesional skin. In conclusion, this study provides novel evidence suggesting that aggressive antibiotic treatment inhibits malignant T cells in lesional skin. Thus, we provide a novel rationale for treatment of SA in advanced CTCL.

U2 - 10.1182/blood.2018888107

DO - 10.1182/blood.2018888107

M3 - Journal article

C2 - 31331920

VL - 134

SP - 1072

EP - 1083

JO - Blood

JF - Blood

SN - 0006-4971

IS - 13

ER -

ID: 226262806